Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 30: Line 30:
 
==Profile Development==
 
==Profile Development==
  
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.some spring cleaning.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016''
+
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016''
  
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.21.some spring cleaning.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 21, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.21.some spring cleaning.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 21, 2016''

Revision as of 21:25, 5 April 2016

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.


Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases


Established Task Forces Currently Working Toward a first Profile with title as follows below:

Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries


Working Documents

Literature Review (Profile 1.0)

Profile Development

Archived versions of the Profile

Statistical Reference Documents

Workflow Documents

Reference Materials